NFKB1 and neoplasm: However, pharmacological inhibition of canonical NF-κB pathway activity by JSH-23 did not strongly suppress RAP tumour-induced lethality, while the NF-κB signalling inhibitor QNZ (EVP4593) enhanced trametinib resistance in RAP tumours.